drugset / Trial / NCT02956382
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Phase 1/2
Completed
24 enrolled
Georgetown University
AbbVie · collabHackensack Meridian Health · collabPharmacyclics LLC. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase I/II study in which patients will be enrolled in a standard 3+3 design. Once the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory grade 1-3a follicular lymphoma, there will be a 17-patient phase II study.
Timeline
- Start
- 2017-03-01
- Primary completion
- 2023-05-23
- Completion
- 2024-03-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | 420 mg | — |
| Subject | Ibrutinib | Small molecule | 560 mg | — |
| Subject | Venetoclax | Small molecule | 400 mg | — |
| Subject | Venetoclax | Small molecule | 600 mg | — |
| Subject | Venetoclax | Small molecule | 800 mg | — |